Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: Rationale, design and methods of BV-HLALCL study: Study protocol
Masahiro Sekimizu, Akihiro Iguchi, Tetsuya Mori, Yuhki Koga, Akiko Kada, Akiko M. Saito, Keizo Horibe
研究成果: ジャーナルへの寄稿 › 学術誌 › 査読
8
被引用数
(Scopus)